Skip to main content

Table 2 Patient characteristics during ICU stay

From: De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety

Characteristics

De-escalation

p

OR [95% CI]

Yes (n = 38)

No (n = 152)

Multifocal colonization

19 (50)

115 (76)

0.002

0.32 [0.15–0.67]

Negative yeast samples

16 (42)

30 (20)

0.004

2.95 [1.4–6.3]

Empirical antifungal treatment

12 (32)

68 (45)

0.14

 

Preemptive antifungal treatment

4 (11)

48 (32)

0.008

0.26 [0.09–0.78]

Targeted antifungal treatment

10 (26)

36 (24)

0.73

 

Proven bacterial infection

10 (26)

0 (0)

< 0.001

NA

Apyrexia > 72 h

37 (97)

123 (81)

0.013

8.7 [1.2–66]

Catecholamine withdrawal at 72 h

29 (76)

89 (59)

0.026

2.57 [1.1–5.98]

Mechanical ventilation

30 (79)

142 (93)

0.006

0.26 [0.09–0.73]

Antibiotic treatment

38 (100)

150 (99)

0.96

 

Total parenteral nutrition

18 (47)

81 (53)

0.51

 

Surgery

21 (55)

76 (50)

0.56

 

Renal replacement therapy

21 (55)

76 (50)

0.56

 

Shock

31 (82)

121 (80)

0.79

 
  1. Data are N (%)
  2. CI confidence interval, OR odds ratio